NLS Pharmaceutics Ltd
NLSP
Company Profile
Business description
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Contact
The Circle 6
Zurich8058
CHET: +41 445122150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
250
Stocks News & Analysis
stocks
16 ASX stocks to buy and hold forever, revisited
This time last year, I highlighted 16 ASX stocks that investors could own indefinitely. One year on, I look at whether there should be any changes to the list of stocks as well as which companies are worth buying now.
stocks
This ASX200 reject could be a contrarian buying opportunity
Johns Lyng’s interim results and index deletion have sent investors running for the exits. Our analyst Esther Holloway thinks the sell-off is overdone.
stocks
A 15 step checklist from Buffett's forgotten inspiration
Phil Fisher achieved remarkable stock market returns by holding high quality growth companies for long periods of time. Here's how he found them.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,973.10 | 130.30 | -1.61% |
| CAC 40 | 7,941.91 | 105.69 | -1.31% |
| DAX 40 | 22,328.77 | 292.18 | -1.29% |
| Dow JONES (US) | 41,433.48 | 478.23 | -1.14% |
| FTSE 100 | 8,495.99 | 104.23 | -1.21% |
| HKSE | 23,623.55 | 158.59 | -0.67% |
| NASDAQ | 17,436.10 | 32.22 | -0.18% |
| Nikkei 225 | 36,850.83 | 57.72 | 0.16% |
| NZX 50 Index | 12,249.55 | 161.42 | -1.30% |
| S&P 500 | 5,572.07 | 42.49 | -0.76% |
| S&P/ASX 200 | 7,756.90 | 133.20 | -1.69% |
| SSE Composite Index | 3,375.17 | 4.66 | -0.14% |